Solriamfetol (obligation for benefit assessment for the first time: excessive daytime sleepiness (EDS) with obstructive sleep apnoea (OSA) after previous therapy)

Subject:

• Active Substance: Solriamfetol
• Name: Sunosi^®
• Therapeutic area: Obstructive sleep apnoea (OSA)
• Pharmaceutical company: Jazz Pharmaceuticals Ireland Ltd.

Time table:

• Start: 01.10.2021
• Final decision by G-BA: 18.03.2022

Final decision:

• No additional benefit proved